Search Results - "Sapin, Hélène"

Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison by Vadher, Karan, Patel, Hiren, Mody, Reema, Levine, Joshua A., Hoog, Meredith, Cheng, Alice YY, Pantalone, Kevin M., Sapin, Hélène

“…Aim To conduct an adjusted indirect treatment comparison (aITC) of the efficacy of tirzepatide 5/10/15 mg versus semaglutide 2 mg in patients with type 2…”
Get full text

The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months by Guerci, Bruno, Giorgino, Francesco, Sapin, Hélène, Boye, Kristina, Lebrec, Jérémie, Federici, Marco Orsini, Heitmann, Elke, Dib, Anne, Füchtenbusch, Martin, García‐Pérez, Luis‐Emilio

“…Aims The primary objective of the TROPHIES observational study is to estimate the duration of treatment on dulaglutide or liraglutide without a significant…”
Get full text

Genotypes and Phenotypes of Children with SHOX Deficiency in France by Rosilio, Myriam, Huber-Lequesne, Céline, Sapin, Hélène, Carel, Jean-Claude, Blum, Werner F, Cormier-Daire, Valérie

“…Context: The prevalence of SHOX deficiency in children with short stature (SS) is variable in the literature and various genotypes have been identified…”
Get full text

The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients ( TROPHIES ): Final patient‐reported outcomes at 24 months by Boye, Kristina S., Lebrec, Jérémie, Dib, Anne, Heitmann, Elke, Federici, Marco Orsini, Yu, Maria, Sapin, Hélène, Barrett, Annabel, Guerci, Bruno, Giorgino, Francesco, Füchtenbusch, Martin, García‐Pérez, Luis‐Emilio

“…Abstract Aim To report health‐related patient‐reported outcomes (PROs) in people with type 2 diabetes (T2D) initiating their first injectable glucose‐lowering…”
Get full text

The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes ( TROPHIES ): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes by Giorgino, Francesco, Guerci, Bruno, Füchtenbusch, Martin, Lebrec, Jérémie, Boye, Kristina, Orsini Federici, Marco, Heitmann, Elke, Dib, Anne, Yu, Maria, Sapin, Hélène, García‐Pérez, Luis‐Emilio

“…Abstract Aims To present the final results of the TROPHIES study (The real‐world observational prospective study of health outcomes with dulaglutide and…”
Get full text

The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy by Barrett, Annabel, Boye, Kristina S, García-Pérez, Luis-Emilio, Giorgino, Francesco, Guerci, Bruno, Füchtenbusch, Martin, Yu, Maria, Sapin, Hélène, Dib, Anne, Heitmann, Elke, Federici, Marco Orsini, Lebrec, Jérémie

“…To describe healthcare resource utilization (HCRU) and associated costs after initiation of injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA)…”
Get more information

Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme by Boye, Kristina S., Thieu, Vivian Thuyanh, Sapin, Hélène, Lee, Clare J., Landó, Laura Fernández, Brown, Katelyn, Bray, Ross, Wiese, Russell J., Patel, Hiren, Rodríguez, Ángel, Yu, Maria

“…Introduction Tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist, is approved for glycaemic control…”
Get full text

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes by Boye, Kristina S., Sapin, Hélène, García-Pérez, Luis-Emilio, Rosilio, Myriam, Orsini Federici, Marco, Heitmann, Elke, Jung, Heike, Aigner, Ulrich, Guerci, Bruno, Giorgino, Francesco, Norrbacka, Kirsi

“…Introduction Although patient-reported outcome (PRO) measures provide important information beyond clinical data, studies that assess the PROs of type 2…”
Get full text

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics by García-Pérez, Luis-Emilio, Boye, Kristina S., Rosilio, Myriam, Jung, Heike, Heitmann, Elke, Norrbacka, Kirsi, Federici, Marco Orsini, Gentilella, Raffaella, Guerci, Bruno, Giorgino, Francesco, Aigner, Ulrich, Sapin, Hélène

“…Introduction The TROPHIES observational study enrolled patients with type 2 diabetes mellitus (T2DM) initiating their first injectable treatment with the…”
Get full text

Utilization of emergency services for severe hypoglycemia in people with diabetes in France: A study based on the national health insurance database by Chartier, Florence, Soulat, Louis, Benabbad, Imane, Sapin, Hélène, Bordier, Lyse, Vainchtock, Alexandre, Raguideau, Fanny, Cash, Roland

“…To estimate the number of people with diabetes (PWD) requiring emergency services for severe hypoglycemia (SH) in France and the associated costs. PWD were…”
Get full text

Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index by Gentilella, Raffaella, Sesti, Giorgio, Vazquez, Luis, Sapin, Hélène, Reed, Victoria, Romera, Irene, Pozzilli, Paolo

“…Aim To assess the relationship between baseline body mass index (BMI) and glycaemic control in dulaglutide‐treated patients, a post hoc analysis was conducted…”
Get full text

Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison by Osumili, Beatrice, Fan, Ludi, Paik, Jim S., Pantalone, Kevin M., Ranta, Kari, Sapin, Hélène, Tofé, Santiago

“…To compare the efficacy and safety of tirzepatide 5, 10 and 15 mg with subcutaneous semaglutide 0.5 mg as second-line treatment for adults with type 2 diabetes…”
Get full text

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial by Gallwitz, Baptist, Prof, Guzman, Juan, MD, Dotta, Francesco, MD, Guerci, Bruno, MD, Simó, Rafael, MD, Basson, Bruce R, MSc, Festa, Andreas, MD, Kiljański, Jacek, MD, Sapin, Hélène, MSc, Trautmann, Michael, MD, Schernthaner, Guntram, Prof

“…Summary Background Glycaemic control deteriorates progressively over time in patients with type 2 diabetes. Options for treatment escalation remain…”
Get full text

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas by DAVIES, Melanie, HELLER, Simon, SREENAN MBBCH, Seamus, SAPIN, Helene, ADETUNJI, Omolara, TAHBAZ, Arash, VORA, Jiten

“…This multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with…”
Get full text

Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6) by Boye, Kristina Secnik, Poon, Jiat Ling, Landó, Laura Fernández, Sapin, Hélène, Huh, Ruth, Wang, Mianbo, Williamson, Suzanne, Patel, Hiren

“…Introduction Patients with type 2 diabetes (T2D) who require intensification of basal insulin therapy need treatment options that can improve their…”
Get full text

Patient characteristics of insulin lispro 200 units/mL users in real world setting in Germany by Schloot, Nanette C., Perez-Nieves, Magaly, Sapin, Hélène, Kruppert, Silvia, Otto, Thorsten, Corrigan, Sheila M., Piras de Oliveira, Carolina

“…Insulin lispro 200 U/mL (IL200) is a treatment choice for people with diabetes who have daily mealtime insulin (MTI) requirements of >20 U/day. We report…”
Get full text

Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide by Boye, Kristina S., Sapin, Hélène, Dong, Wenxiu, Williamson, Suzanne, Lee, Clare J., Thieu, Vivian Thuyanh

“…Introduction Limited data are available on the relationship between quality of life (QoL) change and significant degrees of reduction in glycated haemoglobin…”
Get full text

GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries by Divino, Victoria, DeKoven, Mitch, Khan, Farhad Ali, Boye, Kristina S., Sapin, Hélène, Norrbacka, Kirsi

“…Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a relatively new class of injectable drugs used in the treatment of type 2 diabetes…”
Get full text

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir by Davies, Melanie, Heller, Simon, Sreenan, Seamus, Sapin, Hélène, Adetunji, Omolara, Tahbaz, Arash, Vora, Jiten

“…OBJECTIVE This multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in…”
Get full text

The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12months by Guerci, Bruno, Giorgino, Francesco, Sapin, Hélène, Boye, Kristina, Lebrec, Jérémie, Marco Orsini Federici, Heitmann, Elke, Dib, Anne, Füchtenbusch, Martin, Luis‐Emilio García‐Pérez

“…AimsThe primary objective of the TROPHIES observational study is to estimate the duration of treatment on dulaglutide or liraglutide without a significant…”
Get full text